DSI Renal, Inc, is a wholly owned subsidiary of DaVita, Inc., a Fortune 500 company, which is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and End Stage Renal Disease (ESRD). DSI Renal was formed in 2006 with 106 dialysis centers across the nation. DSI Renal, which had annualized revenue of approximately $360 million was purchased in September, 2011 by DaVita for $690 million, or approximately $6.5 million per location. DaVita provides administrative services to 1,612 outpatient dialysis centers, located in 43 states and serving approximately 125,000 patients, as well as provides acute inpatient dialysis services in nearly 750 hospitals. DaVita is one of the largest kidney care companies in the United States. Their offerings include in-center hemodialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance.

Today, 20 million Americans have been diagnosed with Chronic Kidney Disease (CKD) while another 20 million more are at risk for kidney disease but are unaware of their condition. CKD develops when the kidneys lose most of their ability to remove waste and maintain fluid and chemical balances in the body. ESRD is the most advanced stage of the disease, frequently resulting in kidney failure that requires dialysis treatment. More than 380,000 Americans currently undergo regular dialysis treatment, roughly double the number a decade ago.

Major causes of kidney disease include diabetes (responsible for about 40 percent of all kidney failure) and high blood pressure (responsible for approximately 25 percent of kidney failure). More than 33 percent of kidney failure patients are African American, while the number of Hispanic patients getting ESRD treatment has increased roughly 52 percent within the past decade.

DaVita also operates or provides management and administrative services to 32 outpatient dialysis centers in which it either owns a minority equity investment or which are wholly-owned by third parties. In addition, the company offers infusion therapy services; DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; vascular access services; disease management services and special needs plans; physician services; and clinical research programs. DaVita was rated by Fortune Magazine as one of the top 10 most admired healthcare companies in the United States for the 5th year in a row. DaVita is headquartered in Denver, Colorado and employs over 36,000 people throughout their various divisions across the country. DaVita was rated 359 on the list of the 500 largest corporations published by “Fortune Magazine” in 2011.


DaVita, Inc. is a publicly traded company on the New York Stock Exchange, under the ticker symbol DVA. The company generated revenues of approximately $6.44 billion for the year ending December 31, 2010, with a net income of $405 million. The company reported a shareholder’s equity of approximately $1.88 billion as of June 30, 2011. DaVita is rated BB‑/Stable by Standard and Poors. More information regarding DaVita can be found in Exhibit E as well as by visiting www.davita.com.


© SMB Equity, LLC  © Bradley Associates, LLC  /  DISCLAIMER  /  LOGIN